{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:59:59Z","timestamp":1753887599495,"version":"3.41.2"},"reference-count":65,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Card Fail Rev"],"abstract":"<jats:p>Sacubitril with valsartan (sacubitril\/valsartan) is a relatively novel compound that has become a milestone in the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) in the last decade. Contemporary data suggest that sacubitril\/valsartan is associated with improved outcomes compared with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, and has a greater beneficial effect on myocardial reverse remodelling. Additionally, two recent trials have shown that sacubitril\/valsartan is well-tolerated even in the acute HF setting, thus enabling a continuum of use in the patient\u2019s journey with HFrEF. This article summarises available data on the effectiveness and tolerability of sacubitril\/valsartan in patients with HFrEF, and provides the clinician with practical insights to facilitate the use of this drug in every setting, with an emphasis on acute HF, hypotension, electrolyte imbalance and renal insufficiency.<\/jats:p>","DOI":"10.15420\/cfr.2020.25","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T13:33:46Z","timestamp":1617888826000},"source":"Crossref","is-referenced-by-count":6,"title":["Rationale for and Practical Use of Sacubitril\/Valsartan in the Patient\u2019s Journey with Heart Failure and Reduced Ejection Fraction"],"prefix":"10.15420","volume":"7","author":[{"given":"Mauro","family":"Gori","sequence":"first","affiliation":[{"name":"Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L","family":"Januzzi","sequence":"additional","affiliation":[{"name":"Cardiology Division, Massachusetts General Hospital,  Boston, MA, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6682-0074","authenticated-orcid":false,"given":"Emilia","family":"D\u2019Elia","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinando L","family":"Lorini","sequence":"additional","affiliation":[{"name":"Intensive Care Department, Papa Giovanni XXIII Hospital, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6096","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Owan T, Hodge D, Herges R, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251\u20139. https:\/\/doi.org\/10.1056\/NEJMoa052256; PMID:\u00a016855265.","DOI":"10.1056\/nejmoa052256"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Heidenreich PA, Albert NM, Allen L, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013;6:606\u201319. https:\/\/doi.org\/10.1161\/HHF.0b013e318291329a; PMID:\u00a023616602.","DOI":"10.1161\/hhf.0b013e318291329a"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Benjamin EJ, Blaha MJ, Chiuve SE, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics \u2013 2017 update: a report from the American Heart Association. Circulation 2017;135:e146\u2013603. https:\/\/doi.org\/10.1161\/CIR.0000000000000491; PMID:\u00a028122885.","DOI":"10.1161\/cir.0000000000000491"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Grosu A, Senni M, Iacovoni A, et al. Cardiac resynchronization in combination with beta blocker treatment in advanced chronic heart failure (CARIBE-HF): the results of the CARIBE-HF study. Acta Cardiol 201;66:573\u201380. https:\/\/doi.org\/10.1080\/AC.66.5.2131081; PMID:\u00a022032050.","DOI":"10.1080\/ac.66.5.2131081"},{"key":"ref4","unstructured":"Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 2018;72:351\u201366. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.070; PMID:\u00a030025570."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Psotka MA, Ammon SE, Fiuzat M, et al. Heart failure site-based research in the United States: results of the Heart Failure Society of America Research Network Survey. JACC Heart Fail 2019;7:431\u20138. https:\/\/doi.org\/10.1016\/j.jchf.2019.02.008; PMID:\u00a030981742.","DOI":"10.1016\/j.jchf.2019.02.008"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Claggett B, Packer M, McMurray JJ, et al. Estimating the long-term treatment benefits of sacubitril-valsartan. N Engl J Med 2015;373:2289\u201390. https:\/\/doi.org\/10.1056\/NEJMc1509753; PMID:\u00a026630151.","DOI":"10.1056\/nejmc1509753"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015;36:1990\u201397. https:\/\/doi.org\/10.1093\/eurheartj\/ehv186; PMID:\u00a026022006.","DOI":"10.1093\/eurheartj\/ehv186"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Jhund PS, Fu M, Bayram E, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J 2015;36:2576\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehv330; PMID:\u00a026231885.","DOI":"10.1093\/eurheartj\/ehv330"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 2018;6:489\u201398. https:\/\/doi.org\/10.1016\/j.jchf.2018.02.004; PMID:\u00a029655829.","DOI":"10.1016\/j.jchf.2018.02.004"},{"key":"ref10","unstructured":"Kristensen SL, Martinez F, Jhund PS, et al. Geographic variations in the PARADIGM-HF heart failure trial. Eur Heart J 2016;37:3167\u201374. https:\/\/doi.org\/10.1093\/eurheartj\/ehw226; PMID:\u00a027354044."},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Solomon SD, Claggett B, Desai AS, et al. Influence of ejection fraction on outcomes and efficacy of sacubitril\/valsartan (LCZ696) in heart failure with reduced ejection fraction: the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail 2016;9:e002744. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002744; PMID:\u00a026915374.","DOI":"10.1161\/circheartfailure.115.002744"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Simpson J, Jhund PS, Silva Cardoso J, et al. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol 2015;66:2059\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2015.08.878; PMID:\u00a026541915.","DOI":"10.1016\/j.jacc.2015.08.878"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Kristensen SL, Preiss D, Jhund PS, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail 2016;9:e002560. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002560; PMID:\u00a026754626.","DOI":"10.1161\/circheartfailure.115.002560"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Gori M, Volterrani M, Piepoli M, et al. Angiotensin receptor-neprilysin inhibitor (ARNi): clinical studies on a new class of drugs. Int J Cardiol 2017;226:136\u201340. https:\/\/doi.org\/10.1016\/j.ijcard.2016.06.083; PMID:\u00a027378659.","DOI":"10.1016\/j.ijcard.2016.06.083"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Gori M, Senni M. Sacubitril\/valsartan (LCZ696) for the treatment of heart failure. Expert Rev Cardiovasc Ther 2016;14:145\u201353. https:\/\/doi.org\/10.1586\/14779072.2016.1128827; PMID:\u00a026642078.","DOI":"10.1586\/14779072.2016.1128827"},{"key":"ref16","unstructured":"McMurray J, Packer M, Desai A, et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J 2015;36:434\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehu455; PMID:\u00a025416329."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Solomon SD, Claggett B, Packer M, et al. Efficacy of sacubitril\/valsartan relative to a prior decompensation: the PARADIGM-HF trial. JACC Heart Fail 2016;4:816\u201322. https:\/\/doi.org\/10.1016\/j.jchf.2016.05.002; PMID:\u00a027395349.","DOI":"10.1016\/j.jchf.2016.05.002"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Desai AS, Claggett BL, Packer M, et al. Influence of sacubitril\/valsartan (LCZ696) on 30-day readmission after heart failure hospitalization. J Am Coll Cardiol 2016;68:241\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2016.04.047; PMID:\u00a027417000.","DOI":"10.1016\/j.jacc.2016.04.047"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Okumura N, Jhund PS, Gong J, et al. Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF). Circulation 2016;133:2254\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.020729; PMID:\u00a027143684.","DOI":"10.1161\/circulationaha.115.020729"},{"key":"ref20","unstructured":"Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015;131:54\u201361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013748; PMID:\u00a025403646."},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Desai AS, Vardeny O, Claggett B, et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF Trial. JAMA Cardiol 2017;2:79\u201385. https:\/\/doi.org\/10.1001\/jamacardio.2016.4733; PMID:\u00a027842179.","DOI":"10.1001\/jamacardio.2016.4733"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"B\u00f6hm M, Young R, Jhund PS, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J 2017;38:1132\u201343. https:\/\/doi.org\/10.1093\/eurheartj\/ehw570; PMID:\u00a028158398.","DOI":"10.1093\/eurheartj\/ehw570"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Desai AS, Solomon S, Claggett B, et al. Factors associated with noncompletion during the run-in period before randomization and influence on the estimated benefit of LCZ696 in the PARADIGM-HF Trial. Circ Heart Fail 2016;9:e002735. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002735; PMID:\u00a027296397.","DOI":"10.1161\/circheartfailure.115.002735"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Zile MR, Claggett BL, Prescott MF, et al. Prognostic implications of changes in n-terminal pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol 2016;68:2425\u201336. https:\/\/doi.org\/10.1016\/j.jacc.2016.09.931; PMID:\u00a027908347.","DOI":"10.1016\/j.jacc.2016.09.931"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Vardeny O, Claggett B, Packer M, et al. Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail 2016;18:1228\u201334. https:\/\/doi.org\/10.1002\/ejhf.580; PMID:\u00a027283779.","DOI":"10.1002\/ejhf.580"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Okumura N, Jhund PS, Gong J, et al. Effects of sacubitril\/valsartan in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy. Circ Heart Fail 2016;9:e003212. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.116.003212; PMID:\u00a027618854.","DOI":"10.1161\/circheartfailure.116.003212"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Gori M, Senni M, Metra M. High-sensitive cardiac troponin for prediction of clinical heart failure: are we ready for prime time? Circulation 2017; 135:1506\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.027681; PMID:\u00a028416522.","DOI":"10.1161\/circulationaha.117.027681"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Chandra A, Lewis EF, Claggett BL, et al. Effects of sacubitril\/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol 2018; 3:498\u2013505. https:\/\/doi.org\/10.1001\/jamacardio.2018.0398; PMID:\u00a029617523.","DOI":"10.1001\/jamacardio.2018.0398"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Lewis EF, Claggett BL, McMurray JJV, et al. Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail 2017;10:e003430. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.116.003430; PMID:\u00a028784687.","DOI":"10.1161\/circheartfailure.116.003430"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 2017;5:333\u201340. https:\/\/doi.org\/10.1016\/S2213-8587(17)30087-6; PMID:\u00a028330649.","DOI":"10.1016\/s2213-8587(17)30087-6"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"McMurray J, Packer M, Desai A, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371: 993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077; PMID:\u00a025176015.","DOI":"10.1056\/nejmoa1409077"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Senni M, McMurray JJ, Wachter R, et al. Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail 2016;18:1193\u2013202. https:\/\/doi.org\/10.1002\/ejhf.548; PMID:\u00a027170530.","DOI":"10.1002\/ejhf.548"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Januzzi J, Prescott M, Butler J, et al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 2019;322:1085\u201395. https:\/\/doi.org\/10.1001\/jama.2019.12821; PMID:\u00a031475295.","DOI":"10.1001\/jama.2019.12821"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Desai A, Solomon S, Shah A, et al. Effect of sacubitril-valsartan versus enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2019;322:1077\u201384. https:\/\/doi.org\/10.1001\/jama.2019.12843; PMID:\u00a031475296.","DOI":"10.1001\/jama.2019.12843"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Velazquez E, Morrow D, DeVore A, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2018;380:539\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1812851; PMID:\u00a030415601.","DOI":"10.1056\/nejmoa1812851"},{"key":"ref36","unstructured":"Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail 2019; 21:998\u20131007. https:\/\/doi.org\/10.1002\/ejhf.1498; PMID:\u00a031134724."},{"key":"ref37","unstructured":"Senni M. Monografia Entresto\u00ae (sacubitril\/valsartan). InFocus 2019;XXII(7):1\u201344. https:\/\/springerhealthcare.it\/issue\/anno-xxii-n-7-settembre-2019 (accessed 30 March 2021)."},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"King JB, Shah RU, Bress AP, et al. Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC Heart Fail 2016;4:392\u2013402. https:\/\/doi.org\/10.1016\/j.jchf.2016.02.007; PMID:\u00a027039128.\u00a0","DOI":"10.1016\/j.jchf.2016.02.007"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Sandhu AT, Ollendorf DA, Chapman RH, et al. Cost-effectiveness of sacubitril-valsartan in patients who have heart failure with reduced ejection fraction. Ann Intern Med 2017;166:607\u20138. https:\/\/doi.org\/10.7326\/L17-0044; PMID:\u00a028418550.\u00a0","DOI":"10.7326\/l17-0044"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Gaziano TA, Fonarow GC, Claggett B, et al. Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol 2016; 1: 666\u201372. https:\/\/doi.org\/10.1001\/jamacardio.2016.1747; PMID:\u00a027438344.","DOI":"10.1001\/jamacardio.2016.1747"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Senni M, McMurray JJV, Wachter R, et al. Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril\/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. Eur J Heart Fail 2018;20:491\u2013500. https:\/\/doi.org\/10.1002\/ejhf.1054; PMID:\u00a029164797.","DOI":"10.1002\/ejhf.1054"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Kang DH, Park SJ, Shin SH, et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation 2019;139:1354\u201365. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037077; PMID:\u00a030586756.","DOI":"10.1161\/circulationaha.118.037077"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Senni M, Wachter R, Witte KK, et al. Initiation of sacubitril\/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) HF: a subgroup analysis of the TRANSITION study. Eur J Heart Fail 2020;22:303\u201312. https:\/\/doi.org\/10.1002\/ejhf.1670; PMID:\u00a031820537.","DOI":"10.1002\/ejhf.1670"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Solomon SD, Claggett B, McMurray JJ, et al. Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. Eur J Heart Fail 2016;18:1238\u201343. https:\/\/doi.org\/10.1002\/ejhf.603; PMID:\u00a027364182.","DOI":"10.1002\/ejhf.603"},{"key":"ref45","unstructured":"Wang Y, Zhou R, Lu C, et al. Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis. J Am Heart Assoc 2019;8:e012272. https:\/\/doi.org\/10.1161\/JAHA.119.012272; PMID:\u00a031240976."},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Burnett H, Earley A, Voors AA, et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circ Heart Fail 2017;10(1):e003529. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.116.003529; PMID:\u00a028087688.","DOI":"10.1161\/circheartfailure.116.003529"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Sciatti E, Senni M, Lombardi CM, et al. Sacubitril\/valsartan: from a large clinical trial to clinical practice. J Cardiovasc Med (Hagerstown) 2018;19:473\u20139. https:\/\/doi.org\/10.2459\/JCM.0000000000000687; PMID:\u00a029917003.","DOI":"10.2459\/jcm.0000000000000687"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Packer M, Claggett B, Lefkowitz MP, et al. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol 2018;6:547\u201354. https:\/\/doi.org\/10.1016\/S2213-8587(18)30100-1; PMID:\u00a029661699.","DOI":"10.1016\/s2213-8587(18)30100-1"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Voors AA, Gori M, Liu LC, et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2015; 17:510\u201317. https:\/\/doi.org\/10.1002\/ejhf.232; PMID:\u00a025657064.","DOI":"10.1002\/ejhf.232"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Mc Causland FR, Lefkowitz MP, Claggett B, et al. Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation 2020; 142:1236\u201345. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.047643; PMID:\u00a032845715.","DOI":"10.1161\/circulationaha.120.047643"},{"key":"ref51","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995\u20132008. https:\/\/doi.org\/10.1002\/ejhf.1548; PMID:\u00a031309699."},{"key":"ref52","unstructured":"Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190; PMID:\u00a032865377."},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Solomon SD, Jhund PS, Claggett BL, et al. Effect of dapagliflozin in patients with HFrEF treated with sacubitril\/valsartan: the DAPA-HF Trial. JACC Heart Fail 2020;8:811\u201318. https:\/\/doi.org\/10.1016\/j.jchf.2020.04.008; PMID:\u00a032653447.","DOI":"10.1016\/j.jchf.2020.04.008"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 2020;396:121\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(20)30748-0; PMID:\u00a032446323.","DOI":"10.1016\/s0140-6736(20)30748-0"},{"key":"ref55","unstructured":"Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1908655; PMID:\u00a031475794."},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Solomon SD, Vaduganathan ML, Claggett B, et al. Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure. Circulation 2020;141:352\u201361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044586; PMID:\u00a031736342.","DOI":"10.1161\/circulationaha.119.044586"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Quarta G, Gori M, Iorio A, et al. Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. Eur J Heart Fail 2020;22:1065\u201375. https:\/\/doi.org\/10.1002\/ejhf.1961; PMID:\u00a032654354.","DOI":"10.1002\/ejhf.1961"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"D\u2019Elia E, Vaduganathan M, Gori M, et al. Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. Eur J Heart Fail 2015;17:1231\u20139. https:\/\/doi.org\/10.1002\/ejhf.430; PMID:\u00a026493383.","DOI":"10.1002\/ejhf.430"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Gori M, D\u2019Elia E, Senni M. Sacubitril\/valsartan therapeutic strategy in HFpEF: clinical insights and perspectives. Int J Cardiol 2019;281:158\u201365. https:\/\/doi.org\/10.1016\/j.ijcard.2018.06.060; PMID:\u00a030420146.","DOI":"10.1016\/j.ijcard.2018.06.060"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"B\u00f6hm M, Bewarder Y, Kindermann I. Ejection fraction in heart failure revisited: where does the evidence start? Eur Heart J 2020;41:2363\u20135. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa281; PMID:\u00a032350518.","DOI":"10.1093\/eurheartj\/ehaa281"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Yancy C, Jessup M, Butler J, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017;136:e137\u201361. https:\/\/doi.org\/10.1161\/CIR.0000000000000509; PMID:\u00a028455343.","DOI":"10.1161\/cir.0000000000000509"},{"key":"ref62","unstructured":"Ponikowski P, Voors A, Anker S, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37:2129\u2013200. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128; PMID:\u00a027206819."},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Seferovic P, Ponikowski P, Anker S, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:1169\u201386. https:\/\/doi.org\/10.1002\/ejhf.1531. https:\/\/doi.org\/10.1002\/ejhf.1531; PMID:\u00a031129923.","DOI":"10.1002\/ejhf.1531"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2019;74:1966\u201311. https:\/\/doi.org\/10.1016\/j.jacc.2019.08.001; PMID:\u00a031526538.","DOI":"10.1016\/j.jacc.2019.08.001"}],"container-title":["Cardiac Failure Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2020.25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T13:34:09Z","timestamp":1617888849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2020.25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":65,"URL":"https:\/\/doi.org\/10.15420\/cfr.2020.25","relation":{},"ISSN":["2057-7559","2057-7540"],"issn-type":[{"type":"electronic","value":"2057-7559"},{"type":"print","value":"2057-7540"}],"subject":[],"published":{"date-parts":[[2021,4,5]]},"article-number":"e06"}}